Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has reported significant year-over-year (Y/Y) growth in transplant volumes, particularly with DCD (donation after circulatory death) organs, showcasing a 15% increase in DCD hearts and a remarkable 44% increase in DCD livers. Although overall quarterly transplant volume trends have shown mixed results, the increase in the DCD market has contributed to a 7% growth in the combined heart, liver, and lung transplant market quarter-to-date (QTD). The company anticipates potential upside drivers from new product launches and faster adoption rates in lung transplants, which together may support stronger revenue growth, with expectations for 4Q24 revenue exceeding $120 million, potentially aligning with consensus projections for 1Q25 and 2025.

Bears say

TransMedics Group has experienced a notable decline in donor brain-dead (DBD) organ transplants, with DBD livers and hearts showing decreases of 6% year-over-year, contributing to a broader trend of declining volumes in DBD organs. Despite a slight growth in donor circulatory-dead (DCD) organs, the overall transplant market remains volatile, posing risks to TransMedics' market position, particularly concerning increasing competition and potential share loss. Additionally, while revenue estimates for 2026 have been marginally raised, the decline in group multiples from 7.2x to 6.8x indicates a weakening investor sentiment towards the company's growth potential amidst ongoing challenges.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.